NEW YORK--(BUSINESS WIRE)--Jan. 4, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today it received approval from the FDA (U.S. Food and Drug Administration) to initiate a Phase I/II trial with one of its two lead products, ZIO-101, a novel organic arsenic, in patients with advanced myeloma. This announcement follows a similar approval for a Phase I/II trial for ZIO-201, a novel alkylator, in patients with advanced sarcoma. Patient treatment in both trials is expected to start in early 2006 at leading cancer centers in the U.S., Canada, and U.K. Completion of enrollment is expected by the end of 2006, followed by pivotal trials beginning mid-2007.
